NeurAxis, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a medical technology company built around PENFS neuromodulation. Its 8-K reports cover preliminary operating results, FDA 510(k) clearance for PENFS indications, at-the-market common stock offering arrangements under a Form S-3 registration statement, related prospectus supplements and legal opinions, and material agreements involving licensed neuromodulation assets.
NeurAxis proxy materials disclose annual meeting matters, director elections, auditor ratification, equity incentive plan amendments, an employee stock purchase plan, and voting rights involving common stock and Series B Preferred Stock. The filing record also documents corporate governance, stock-based compensation plans, material contract changes, and risk-bearing financing mechanisms tied to its commercialization strategy.
Neuraxis, Inc. disclosed preliminary, unaudited results for the quarter and nine months ended September 30, 2025. The company expects cash and cash equivalents of approximately $4.4 million as of September 30, 2025.
For the three months ended September 30, 2025, Neuraxis estimates net sales of about $0.8 million, gross profits of about $0.7 million, and an operating loss of about $2.1 million. For the nine months ended September 30, 2025, net sales are expected to be about $2.6 million, compared with about $1.9 million for the same period in 2024.
Management emphasized these figures are preliminary and subject to change as the quarter-end close is completed. The company’s independent registered public accounting firm has not audited or reviewed these estimates, and final financial statements will be completed subsequent to this report. The company cautioned that adjustments could be material and advised against undue reliance on these preliminary figures.
NeurAxis, Inc. amended its at-the-market program to offer and sell shares of common stock with an aggregate offering price of up to $6,270,000 through Craig-Hallum, subject to General Instruction I.B.6 of Form S-3.
The company reports it has not sold any securities under the Sales Agreement from August 29, 2025 through October 23, 2025. On a preliminary unaudited basis, cash and cash equivalents were approximately $4.4 million as of September 30, 2025. For Q3 2025, preliminary net sales were approximately $0.8 million, gross profits approximately $0.7 million, and operating loss approximately $2.1 million. For the nine months ended September 30, 2025, preliminary net sales were approximately $2.6 million versus approximately $1.9 million for the prior-year period.
As of October 23, 2025, public float was approximately $33,817,486, based on 9,986,294 shares outstanding and a $3.82 share price, and the company has sold $4,999,998 of securities under I.B.6 in the prior 12 months.
Neuraxis (NRXS): Passive ownership disclosed. Bigger Capital Fund, LP and related entities filed a Schedule 13G stating passive beneficial ownership of Neuraxis common stock. As of October 9, 2025, Bigger Capital and its GP reported 583,998 shares, or 5.92% of the class. District 2 Capital Fund LP reported 105,561 shares, or 1.07%. Aggregating indirect interests, Michael Bigger may be deemed to beneficially own 689,559 shares, or 6.99%.
The filing cites 9,858,716 shares outstanding as of June 30, 2025 (per the company’s Form 10-Q) as the basis for percentages. It also notes warrants that are subject to a 9.99% beneficial ownership limitation and therefore excluded from the reported amounts: 66,138 shares tied to Bigger Capital and 79,366 shares tied to District 2 Capital Fund LP. The certification states the securities were not acquired to change or influence control.
Neuraxis, Inc. filed a Form S-8 registration statement to register securities issuable under its 2025 Employee Stock Purchase Plan and its existing 2022 Omnibus Securities and Incentive Plan. These plans are used to grant stock-based compensation and allow employees and other eligible participants to acquire company shares as part of their compensation packages.
The filing incorporates by reference Neuraxis’s most recent Annual Report on Form 10-K for the year ended December 31, 2024, its Quarterly Reports on Form 10-Q for the first two quarters of 2025, and several Current Reports on Form 8-K, along with the description of its common stock. Neuraxis also describes indemnification protections for directors and officers under Delaware law, its bylaws and potential insurance coverage. The registration statement is signed by the Chief Executive Officer, Chief Financial Officer and the board of directors.
Brian Allen Carrico, Neuraxis, Inc. director and CEO, reported grants of restricted stock units (RSUs). The Form 4 shows three RSU grants: 10,000 shares (reported 03/04/2025) with a reported value per share of $2.18; 90,640 shares (reported 03/04/2025) at $2.18; and 70,019 shares (reported 01/03/2025) at $2.42. Each grant is described as restricted stock units that will vest in full at the end of 36 months under Neuraxis’s incentive plans. The table reports the number of shares beneficially owned following each reported transaction equal to the amounts granted. The filing is individually reported by Carrico and is signed on 09/10/2025.
Kristin Ferge, a director of Neuraxis, Inc. (NRXS), reported a non-derivative acquisition of common stock on 01/17/2025. She acquired 13,157 shares at a price of $2.85 per share. Following this transaction, Ms. Ferge beneficially owned 14,340 shares. The filing states these shares were issued as compensation for services rendered as an independent director of the company. The Form 4 shows the filing is made by one reporting person and includes the reporting person’s address in Carmel, IN.
Neuraxis, Inc. (NRXS) reporting person Timothy Robert Henrichs received restricted stock unit (RSU) awards as compensation and hiring/bonus grants totaling 242,017 RSUs across four grants. The reported grant dates are 01/03/2025, 03/04/2025 and 03/18/2025. Each grant is described as vesting in full at the end of 36 months. The awards convert into an equal number of common shares upon vesting: 8,037; 100,000; 66,000; and 67,980 shares respectively. The Form 4 lists per-share figures of $2.43 for the 03/18/2025 and 01/03/2025 grants and $2.18 for the 03/04/2025 grant, and indicates these RSUs were granted as compensation for services as an independent director, a hiring grant, a bonus, and under the Long-Term Incentive Plan. The filing is signed by the reporting person on 09/10/2025.
Neuraxis, Inc. (NRXS) director Jane Elizabeth Keyser received 13,157 shares of common stock as compensation for board service. The transaction was executed on 01/17/2025 at a reported price of $2.85 per share, leaving the reporting person with 24,737 shares beneficially owned following the issuance. The Form 4 identifies Keyser as a director and the shares were issued specifically as independent director compensation. The filing is signed by Beth Keyser on 09/10/2025 and includes the reporting person’s address in Carmel, Indiana.
Neuraxis, Inc. reported a Form 4 showing that Adrian Miranda, CMO and SVP Science & Tech, was granted restricted stock units (RSUs) totaling 75,000 underlying shares in three separate awards. The grants are identified as 10,000, 30,000 and 35,000 RSUs and show per-share prices of $2.18 for two awards and $2.42 for one award. The filing states each RSU award will vest in full after 36 months. The reporting person is a company officer and the Form 4 was signed by Adrian Miranda.
Neuraxis, Inc. (NRXS) reported an insider equity grant to director Bradley M. Watkins. On 01/17/2025 Mr. Watkins was issued 13,157 shares of common stock as compensation for his services as an independent director at an effective price of $2.85 per share. After the issuance he beneficially owned 24,737 shares in a direct ownership form. The Form 4 was signed by Mr. Watkins on 09/10/2025. This filing records a routine director compensation equity award and does not include derivative transactions.